![](https://flagship-pioneering.transforms.svdcdn.com/production/NetworkMedicines.png?w=800&h=1000&auto=compress%2Cformat&fit=crop&dm=1713208944&s=9363e41b406a05d5447e5920cb3e3d16)
![](https://flagship-pioneering.transforms.svdcdn.com/production/Flashcardsmark-1-copy.png?w=929&h=263&auto=compress%2Cformat&fit=crop&dm=1681830280&s=581de83f03f7582c708109893a6e7ba3)
Network Medicines™
: a new class of therapeutics that reprogram diseased cells to release a defined array of signals that precisely coordinate multicellular networks to drive disease resolution
Video 07.10.2024
Noubar Afeyan, Flagship Founder & CEO, discusses Flagship's capital raise of $3.6 billion to support the creation and development of breakthrough companies in human health, sustainability, and artificial intelligence. For more on Flagship's recent advances including key partnerships, global expansion and expanded top talent, read the full announcement.